Cystic Fibrosis - A Pipeline Analysis Report

Overview of the drug development for cystic fibrosis

Cystic fibrosis is a genetic defect, which builds up thick mucus in the lungs. The thick mucus blocks the airways and damages the lungs, leading to bacterial infection. These bacteria when multiplied may often lead to a serious chronic problem. However, regular treatment can reduce these complications and ease symptoms. Also, in some instances, it has also been observed that the people with bronchiectasis tend to develop cystic fibrosis in the long term, leading to failure in the respiratory system. It generally occurs due to a defect in both the copies of the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. People with cystic fibrosis have high salt levels, and the severity of cystic fibrosis differs from person to person. Globally, over 70,000 people are living with cystic fibrosis with about 30,000 of them hailing from the US. Consequently, Technavio’s market research analysts suggest that rising number of incidences of cystic fibrosis is one of the key factors promoting the drug development for cystic fibrosis.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for treatment of cystic fibrosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of gene therapy molecules for the treatment of cystic fibrosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AstraZeneca
• Anthera Pharmaceuticals
• Celtaxsys

Therapeutic assessment of the drug development for cystic fibrosis by route of administration

• Oral
• Inhalation
• Intravenous
• Subcutaneous

The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity.

Therapeutic assessment of the drug development for cystic fibrosis by therapy

• Monotherapy
• Combination therapy
• Unknown

According to this pipeline analysis report, all the molecules that are currently in the drug development for cystic fibrosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for cystic fibrosis?
• What are the companies that are currently involved in the drug development molecules for cystic fibrosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.